Moupali Das

5.3k total citations · 2 hit papers
63 papers, 2.5k citations indexed

About

Moupali Das is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Moupali Das has authored 63 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Infectious Diseases, 26 papers in Epidemiology and 24 papers in Virology. Recurrent topics in Moupali Das's work include HIV/AIDS Research and Interventions (41 papers), HIV/AIDS drug development and treatment (34 papers) and HIV Research and Treatment (24 papers). Moupali Das is often cited by papers focused on HIV/AIDS Research and Interventions (41 papers), HIV/AIDS drug development and treatment (34 papers) and HIV Research and Treatment (24 papers). Moupali Das collaborates with scholars based in United States, United Kingdom and France. Moupali Das's co-authors include Grant Colfax, Glenn‐Milo Santos, Eric Vittinghoff, Priscilla Lee Chu, Susan Scheer, Willi McFarland, Paul E. Sax, Lijie Zhong, Christoph C Carter and Frank A. Post and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Moupali Das

59 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco

2010 590 citations Moupali Das, Priscilla Lee Chu et al. PLoS ONE profile →
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

2019 468 citations Paul E. Sax, Grace A. McComsey et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Moupali Das United States	23	2.0k	1.1k	899	841	281	63	2.5k
Richard Elion United States	21	1.5k 0.7×	562 0.5×	826 0.9×	438 0.5×	158 0.6×	46	1.8k
Seble Kassaye United States	24	1.3k 0.7×	675 0.6×	505 0.6×	466 0.6×	519 1.8×	135	2.1k
Allan Rodríguez United States	28	1.6k 0.8×	1.1k 1.0×	533 0.6×	355 0.4×	609 2.2×	120	2.2k
David Asboe United Kingdom	23	1.1k 0.5×	731 0.7×	458 0.5×	235 0.3×	157 0.6×	67	1.6k
Lorie Benning United States	22	936 0.5×	579 0.5×	493 0.5×	858 1.0×	164 0.6×	44	1.9k
Silvia Guillemi Canada	24	1.1k 0.6×	998 0.9×	405 0.5×	287 0.3×	222 0.8×	74	1.7k
Esther Robison United States	19	877 0.4×	421 0.4×	426 0.5×	578 0.7×	312 1.1×	32	1.6k
Katherine Tassiopoulos United States	26	1.2k 0.6×	633 0.6×	492 0.5×	935 1.1×	528 1.9×	79	2.2k
Jennifer Cocohoba United States	24	1.0k 0.5×	466 0.4×	255 0.3×	306 0.4×	205 0.7×	62	1.5k
Samuel A. Bozzette United States	7	1.8k 0.9×	1.2k 1.1×	412 0.5×	445 0.5×	550 2.0×	9	2.3k

Countries citing papers authored by Moupali Das

Since Specialization

Citations

This map shows the geographic impact of Moupali Das's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moupali Das with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moupali Das more than expected).

Fields of papers citing papers by Moupali Das

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moupali Das. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moupali Das. The network helps show where Moupali Das may publish in the future.

Co-authorship network of co-authors of Moupali Das

This figure shows the co-authorship network connecting the top 25 collaborators of Moupali Das. A scholar is included among the top collaborators of Moupali Das based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moupali Das. Moupali Das is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parkin, Neil, Fei Gao, Eduard Grebe, et al.. (2022). Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. Clinical Pharmacology & Therapeutics. 114(1). 29–40. 10 indexed citations

Cespedes, Michelle, Moupali Das, Maria Prins, et al.. (2022). Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial. Transgender Health. 9(1). 46–52. 10 indexed citations

Cespedes, Michelle, Moupali Das, J. Carlo Hojilla, et al.. (2022). Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLoS ONE. 17(6). e0267780–e0267780. 23 indexed citations

Huhn, Gregory, Moti Ramgopal, Mamta K. Jain, et al.. (2020). HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. PLoS ONE. 15(1). e0224875–e0224875. 5 indexed citations

Bekerman, Elena, Stephanie Cox, Darius Babusis, et al.. (2020). Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection. Journal of Antimicrobial Chemotherapy. 76(3). 692–698. 13 indexed citations

Ys, Kim, Shinichi Oka, Ploenchan Chetchotisakd, et al.. (2019). Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. SHILAP Revista de lepidopterología. 20(3). 73–81. 9 indexed citations

Yilmaz, Aylin, Richard W. Price, Staffan Nilsson, et al.. (2019). Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS ONE. 14(12). e0226276–e0226276. 16 indexed citations

Rizzardini, Giuliano, François Raffi, Federico Pulido, et al.. (2019). Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. The Lancet HIV. 6(10). e655–e666. 32 indexed citations

Begley, Rebecca, Moupali Das, Lijie Zhong, et al.. (2018). Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 78(4). 465–472. 37 indexed citations

10.

Margot, Nicolas, Stephanie Cox, Moupali Das, et al.. (2018). Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks. Journal of Clinical Virology. 103. 37–42. 16 indexed citations

11.

Funderburg, Nicholas, Grace A. McComsey, Manjusha Kulkarni, et al.. (2016). Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. EBioMedicine. 13. 321–327. 19 indexed citations

12.

Wohl, David A., Shinichi Oka, Nathan Clumeck, et al.. (2016). Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes. 72(1). 58–64. 145 indexed citations

13.

Mills, Anthony, Gordon Crofoot, Cheryl McDonald, et al.. (2015). Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(4). 439–445. 121 indexed citations

14.

Hernández, Diana, Daniel J. Feaster, Lauren Gooden, et al.. (2015). Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. AIDS and Behavior. 20(1). 204–214. 3 indexed citations

15.

Santos, Glenn‐Milo, Phillip O. Coffin, Eric Vittinghoff, et al.. (2014). Substance use and drinking outcomes in Personalized Cognitive Counseling randomized trial for episodic substance-using men who have sex with men. Drug and Alcohol Dependence. 138. 234–239. 35 indexed citations

16.

Knight, Kelly R., Moupali Das, Erin DeMicco, et al.. (2013). A Roadmap for Adapting an Evidence-Based HIV Prevention Intervention: Personal Cognitive Counseling (PCC) for Episodic Substance-Using Men Who Have Sex with Men. Prevention Science. 15(3). 364–375. 15 indexed citations

17.

Santos, Glenn‐Milo, Phillip O. Coffin, Moupali Das, et al.. (2013). Dose-Response Associations Between Number and Frequency of Substance Use and High-Risk Sexual Behaviors Among HIV-Negative Substance-Using Men Who Have Sex With Men (SUMSM) in San Francisco. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 540–544. 63 indexed citations

18.

Korthuis, P. Todd, Daniel J. Feaster, Moupali Das, et al.. (2011). Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness. Addictive Behaviors. 37(4). 552–555. 20 indexed citations

19.

Santos, Glenn‐Milo, Moupali Das, & Grant Colfax. (2011). Interventions for Non-Injection Substance Use Among US Men Who Have Sex with Men: What is Needed. AIDS and Behavior. 15(S1). 51–56. 33 indexed citations

20.

Das, Moupali, Tim Matheson, Glenn‐Milo Santos, et al.. (2010). Feasibility and acceptability of a phase II randomized pharmacologic intervention for methamphetamine dependence in high-risk men who have sex with men. AIDS. 24(7). 991–1000. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact